MOTS-c 20MG
$77.00
10 in stock
Dosage Information
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 6 units (0.06 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 9 units (0.09 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 12 units (0.12 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 15 units (0.15 mL) |
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 – 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 – 24 units (0.24 mL |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 – 18 units (0.18 mL) |
- Labs Attested
- COA Included
- For 21+ Only
- US Sourced
Product Description:
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR. It is naturally encoded in the mitochondrial DNA (specifically a short open reading frame in the 12S rRNA region) and produced in response to metabolic stress, exercise, or fasting.
Unlike most peptides, it originates from the mitochondria (the cell’s energy powerhouses) and acts as a signaling molecule that communicates between mitochondria and the nucleus, influencing systemic metabolism.
How It Works
MOTS-c functions primarily as a metabolic regulator and exercise mimetic:
- AMPK activation: It increases levels of AICAR (an AMPK activator), turning on AMP-activated protein kinase — the “metabolic master switch” that promotes energy production, glucose uptake, and fat oxidation while inhibiting energy storage.
- Folate-AICAR-AMPK pathway: This leads to improved mitochondrial function, biogenesis (via PGC-1α and SIRT1), and metabolic flexibility.
- Insulin sensitivity and glucose handling: Enhances glucose utilization in skeletal muscle and reduces insulin resistance.
- Fat metabolism: Promotes lipolysis, fatty acid oxidation, browning of white fat, and reduces fat accumulation (especially in liver and adipose tissue).
- Nuclear gene regulation: Translocates to the nucleus to modulate gene expression related to stress response, inflammation, and aging.
It mimics many benefits of exercise and calorie restriction at the cellular level, helping maintain energy homeostasis under stress.
Potential Benefits and Why People Use It
In preclinical research (mostly animal and in-vitro studies) and emerging human interest, MOTS-c is explored for:
- Metabolic health and fat loss — Improves insulin sensitivity, boosts fat burning, reduces obesity, and targets visceral fat.
- Exercise performance and recovery — Enhances endurance, physical capacity (even in older models), muscle metabolism, and adaptation to training.
- Anti-aging and longevity — Supports mitochondrial function, reduces age-related decline, and may protect against metabolic diseases associated with aging.
- Additional effects — Potential benefits for inflammation reduction, bone metabolism, cardiovascular function, and cognitive health.
It is popular in fitness, bodybuilding, longevity, and regenerative communities as a “exercise in a vial” option, often stacked with other peptides for comprehensive metabolic and recovery support.
Important Caveats
- Limited human evidence: Strong preclinical data exists, but large-scale, long-term human clinical trials are lacking. Most benefits are demonstrated in animal models.
- Regulatory status: Not FDA-approved for any medical use. It is considered a research chemical and is on the FDA’s Category 2 bulk substances list (significant safety risks for compounding). Banned by WADA for athletes.
- Safety: Generally well-tolerated in studies with low toxicity in animals, but human data is limited. Anecdotal side effects include injection-site reactions, heart palpitations, insomnia, or fatigue. Theoretical concerns involve metabolic dysregulation or effects on homocysteine/folate pathways. Long-term safety is unknown.
Bottom line: MOTS-c is a fascinating mitochondrial peptide that acts as a potent metabolic regulator and exercise mimetic, with strong potential for improving insulin sensitivity, fat loss, energy metabolism, and healthy aging. For your EDB LLC peptide products, highlight its research-grade nature, include robust disclaimers, emphasize quality sourcing, and always stress the need for professional medical advice. As with your other offerings (BPC-157, TB-500, IGF-1 LR3, Tesamorelin, etc.), position it educationally in the experimental/research context.
You may also research
Related Compounds
BPC 157\TB-500
- Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
- Typical daily range: 200–600 mcg once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
BPC-157
BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.
- Typical daily range: 200–600 mcg once daily (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Route: Subcutaneous | Frequency: Once daily
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
CJC-1295 no DAC\Ipamorelin
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
- Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
GKC-CU 100MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~33.3 mg/mL concentration.
- Typical daily range: 1–2 mg once daily (gradual titration over 12 weeks).
- Easy measuring: At 33.3 mg/mL, 1 unit = 0.01 mL ≈ 333 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 1.0 mg | 3 units (0.03 mL) |
| Weeks 5–8 | 1.5 mg | 4.5 units (0.045 mL) |
| Weeks 9–12 | 2.0 mg | 6 units (0.06 mL) |
GLOW
- Reconstitute: Add 3.0 mL bacteriostatic water → ~23.3 mg/mL concentration.
- Typical daily dose: 2,330 mcg (2.33 mg) once daily for 4 weeks.
- Easy measuring: At 33.3 mg/mL, 1 unit = 0.01 mL ≈ 333 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2,330 mcg | 70.5 units (0.70 mL) |
IGF1-LR3
- Reconstitute: Add 3.0 mL bacteriostatic water → ~0.333 mg/mL concentration (333 mcg/mL).
- Typical daily range: 20–50 mcg once daily subcutaneously (gradual titration recommended).
- Easy measuring: At 0.333 mg/mL, 1 unit = 0.01 mL ≈ 3.33 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) for up to 12 months; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid repeated freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
MOTS-c 20MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 6 units (0.06 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 9 units (0.09 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 12 units (0.12 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 15 units (0.15 mL) |
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 - 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 - 24 units (0.24 mL |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 - 18 units (0.18 mL) |
MOTS-C 40MG
- Reconstitute: Add 3.0 mL bacteriostatic water → ~13.33 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 13.33 mg/mL, 1 unit = 0.01 mL ≈ 133.3 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–2 | 200 mcg (0.2 mg) | 1.5 units (0.015 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 3 units (0.03 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 4.5 units (0.045 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 6 units (0.06 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 7.5 units (0.075 mL) |
PT-141
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Retatrutide 20MG
- Reconstitute: Add 2.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
- Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
- Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) |
| Weeks 9–12 | 6 mg (6000 mcg) | 60 units (0.60 mL) |
| Weeks 13+ | 8 mg (8000 mcg) | 80 units (0.80 mL) |
Retatrutide 40MG
- Reconstitute: Add 2.0 mL bacteriostatic water → ~20.0 mg/mL concentration.
- Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
- Easy measuring: At 20.0 mg/mL, 1 unit = 0.01 mL ≈ 200 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
| Weeks 1–4 | 2 mg (2000 mcg) | 10 units (0.10 mL) |
| Weeks 5–8 | 4 mg (4000 mcg) | 20 units (0.20 mL) |
| Weeks 9–12 | 6 mg (6000 mcg) | 30 units (0.30 mL) |
| Weeks 13+ | 8 mg (8000 mcg) | 40 units (0.40 mL) |
